Brian Goff
Known title: Chief Executive OfficerCIK: 0001546216
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
Transaction History
| NTLA | ▲ Buy | Grant | 9,200 | $0 | 6/9/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,528 | $0 | 4/2/2026 | View on chart |
| AGIO | ▼ Sell | Open Market | 12,472 | $433K | 4/2/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 13,500 | $0 | 4/2/2026 | View on chart |
| AGIO | ▼ Sell | Open Market | 6,596 | $229K | 4/2/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 8,500 | $0 | 3/2/2026 | View on chart |
| AGIO | ▼ Sell | Open Market | 3,870 | $112K | 3/2/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 18,000 | $0 | 3/2/2026 | View on chart |
| AGIO | ▼ Sell | Open Market | 8,267 | $239K | 3/2/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 13,000 | $0 | 3/2/2026 | View on chart |
| AGIO | ▼ Sell | Open Market | 5,918 | $171K | 3/2/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,528 | $0 | 12/30/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 12,473 | $338K | 12/30/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 12,750 | $0 | 12/30/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 6,230 | $169K | 12/30/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 22,691 | $0 | 8/8/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 11,085 | $406K | 8/8/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,527 | $0 | 6/24/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 12,471 | $418K | 6/24/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 12,750 | $0 | 6/24/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 6,229 | $209K | 6/24/2025 | View on chart |
| NTLA | ▲ Buy | Grant | 8,000 | $0 | 6/11/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 4,153 | $148K | 3/3/2025 | View on chart |
| AGIO | ▼ Sell | Open Market | 8,794 | $313K | 3/3/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 8,500 | $0 | 3/1/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 18,000 | $0 | 3/1/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 22,691 | $0 | 8/8/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 11,091 | $474K | 8/8/2024 | View on chart |
| NTLA | ▲ Buy | Grant | 15,409 | $0 | 6/13/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,527 | $0 | 6/5/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 12,115 | $592K | 6/5/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 4,156 | $135K | 3/5/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 8,500 | $0 | 3/1/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 7,635 | $165K | 1/24/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 17,018 | $0 | 1/20/2024 | View on chart |
| AGIO | ▼ Sell | Open Market | 12,066 | $277K | 1/9/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,527 | $0 | 1/5/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 22,691 | $0 | 8/8/2023 | View on chart |
| AGIO | ▼ Sell | Open Market | 10,178 | $259K | 8/8/2023 | View on chart |
| AGIO | ▼ Sell | Open Market | 11,449 | $325K | 6/30/2023 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 25,528 | $0 | 6/28/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Intellia Therapeutics Appoints New Chief Medical Officer
Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.
Intellia Therapeutics Appoints New Chief Medical Officer. Intellia Therapeutics announced the appointment of Jing L. Marantz as its new Chief Medical Officer. This leadership change occurred as the stock recently rose 7.6%, moving away from recent support levels. The news highlights a strategic shift in the company's medical leadership during a period of increased market activity.